Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma

Immunotherapy has recently become a promising cancer therapy with extensive applications of immune checkpoint inhibitors (ICIs). However, pancreatic ductal adenocarcinoma (PDAC) appears to be unresponsive to immunotherapy due to the immunosuppressive microenvironment. Recent studies showed that canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Yang, Liu, Heshu, Zhang, Yuanyuan, Liu, Jian, Yan, Rui, Xiao, Zeru, Fan, Xiaona, Huang, Xuying, An, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739467/
https://www.ncbi.nlm.nih.gov/pubmed/34998236
http://dx.doi.org/10.1016/j.tranon.2021.101317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739467/
https://www.ncbi.nlm.nih.gov/pubmed/34998236
http://dx.doi.org/10.1016/j.tranon.2021.101317

Ejemplares similares